APA (7th ed.) Citation

A, M., B, N., H, W., G, S., MV, D., A, K., . . . T, F. (2025). Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: A study protocol of ARIADNE. BMJ open, 15(8), e102626. https://doi.org/10.1136/bmjopen-2025-102626

Chicago Style (17th ed.) Citation

A, Matikas, et al. "Randomised Trial of Trastuzumab Deruxtecan and Biology-driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer: A Study Protocol of ARIADNE." BMJ Open 15, no. 8 (2025): e102626. https://doi.org/10.1136/bmjopen-2025-102626.

MLA (9th ed.) Citation

A, Matikas, et al. "Randomised Trial of Trastuzumab Deruxtecan and Biology-driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer: A Study Protocol of ARIADNE." BMJ Open, vol. 15, no. 8, 2025, p. e102626, https://doi.org/10.1136/bmjopen-2025-102626.